You are here: Industry Insights > NASH

News List

Hepagene Therapeutics, Inc, Announces Dosing of First Healthy Subject in a Phase I Study of HPG1860 for NASH En-CPhI.CN
October 17, 2019
Hepagene Therapeutics, Inc, a clinical stage drug discovery and development company which devotes its efforts towards discovering ...
Galmed Initiated Study of Aramchol in Subjects with NASH and Fibrosis americanpharmaceuticalreview
September 27, 2019
Galmed Pharmaceuticals announced the initiation of its Phase 3/4 ARMOR clinical study to evaluate the efficacy and safety of Aramchol in subjects with NASH and fibrosis. This double-blind, placebo-controlled ...
NST Doses First Patient in Phase 2b Clinical Study of Icosabutate in NASH (‘ICONA’) b3cnewswire
September 26, 2019
NorthSea Therapeutics B.V., (‘NST’) a Dutch biotech company developing novel and innovative strategies for the treatment of NASH (Non-alcoholic Steatohepatitis) and other metabolic ...
Terns Announces Positive Interim Results from Ongoing Trial of TERN-201 americanpharmaceuticalreview
August 14, 2019
Terns Pharmaceuticals announced the interim results of an ongoing Phase 1 clinical trial of TERN-201, a semicarbazide-sensitive amine oxidase (SSAO) inhibitor, being developed for the treatment of NASH.
89bio Initiates Trial of BIO89-100 for NASH americanpharmaceuticalreview
August 09, 2019
89Bio announced the first patients have been screened in its proof of concept Phase 1b/2a clinical trial evaluating its investigational product candidate, BIO89-100, a glycoPEGylated analog of fibroblast growth factor 21 (FGF21) ...
Gilead Sciences, Renown Institute for Health Innovation collaborate for NASH biospectrumasia
July 16, 2019
Under the terms of the collaboration and license agreement, Gilead will provide funding to Renown IHI to sequence and analyze the DNA of 15,000 individuals living with NASH or nonalcoholic fatty liver disease (NAFLD) as well as a control cohort of 40,000
Madrigal Pharma Appoints President of R&D contractpharma
July 12, 2019
Rebecca Taub to head Phase III development of resmetirom in both NASH and earlier stage dyslipidemias.
Boehringer, Yuhan Enter NASH Pact contractpharma
July 09, 2019
To develop dual agonist for the treatment of NASH and related liver diseases that combines GLP-1 and FGF21 activity in one molecule.
Akero Announces Dosing of First Patient in NASH Study americanpharmaceuticalreview
July 04, 2019
Akero Therapeutics announced the dosing of the first patient in its Phase 2a clinical study of AKR-001, a novel FGF21 analog, for the treatment of NASH (the BALANCED study).
GENFIT, Terns Pharmaceuticals to Commercialize Elafibranor in China contractpharma
June 28, 2019
For treatment of non-alcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC).

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page